Voyager Therapeutics (VYGR) Stock Forecast & Price Target

Compare

1,316 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

VYGR Analyst Ratings

Strong Buy

8 Buy

0 Hold

0 Sell

Based on 8 analysts giving stock ratings to

Voyager

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

VYGR Stock 12 Month Forecast

Average Price Target

$14.00

▲(217.46% Upside)

Based on 8 Wall Street analysts offering 12 month price targets for Voyager Therapeutics in the last 3 months. The average price target is $14.00 with a high forecast of $25.00 and a low forecast of $8.00. The average price target represents a 217.46% change from the last price of $4.41.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","26":"$26","7.25":"$7.25","13.5":"$13.5","19.75":"$19.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$25.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$14.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$8.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,7.25,13.5,19.75,26],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.95,5.569230769230769,7.188461538461539,8.807692307692307,10.426923076923078,12.046153846153846,13.665384615384614,15.284615384615385,16.903846153846153,18.523076923076925,20.142307692307693,21.76153846153846,23.38076923076923,{"y":25,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.95,4.723076923076923,5.496153846153846,6.26923076923077,7.042307692307693,7.815384615384616,8.588461538461539,9.361538461538462,10.134615384615385,10.907692307692308,11.680769230769231,12.453846153846154,13.226923076923079,{"y":14,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.95,4.2615384615384615,4.573076923076924,4.884615384615385,5.196153846153846,5.507692307692308,5.819230769230769,6.130769230769231,6.4423076923076925,6.753846153846154,7.065384615384616,7.376923076923077,7.688461538461539,{"y":8,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6.93,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.67,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.45,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.08,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.37,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.55,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.29,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.12,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.96,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.58,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.68,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.67,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.95,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$25.00

Average Price Target$14.00

Lowest Price Target$8.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Patrick Trucchio

H.C. Wainwright

$25

Buy

466.89%

Upside

Reiterated

12/03/25

H.C. Wainwright Sticks to Their Buy Rating for Voyager Therapeutics (VYGR)We reiterate our Buy ratings on Alnylam, Biogen, Arrowhead, Denali, Prothena, AC Immune, Voyager, and Alector.

Unknown Analyst

Wells Fargo

Not Ranked

Wells Fargo

$10

Buy

126.76%

Upside

Reiterated

11/12/25

Voyager Therapeutics (VYGR) Receives a Buy from Wells Fargo

Joon Lee

Truist Financial

―

Buy

―

Reiterated

11/11/25

Analysts Offer Insights on Healthcare Companies: Alpha Teknova (NASDAQ: TKNO), Voyager Therapeutics (NASDAQ: VYGR) and Terns Pharmaceuticals (NASDAQ: TERN)

Sumant Kulkarni

Canaccord Genuity

$12

Buy

172.11%

Upside

Reiterated

11/11/25

Voyager Therapeutics (VYGR) Gets a Buy from Canaccord Genuity

Yun Zhong

Wedbush

Buy

81.41%

Upside

Reiterated

11/11/25

Wedbush Keeps Their Buy Rating on Voyager Therapeutics (VYGR)ReiterateOutperform rang and $8 PT on VYGR based on the company's increasingly diversified approaches that we believe should help to increase the overall likelihood of success in developing novel therapeutics for CNS disorders.

Phil Nadeau

TD Cowen

―

Buy

―

Reiterated

11/10/25

Voyager Therapeutics: Strong Financial Position and Promising Pipeline Justify Buy Rating

Lili (Aurélie) Nsongo

Leerink Partners

$12→$11

Buy

149.43%

Upside

Reiterated

11/10/25

Voyager Therapeutics price target lowered to $11 from $12 at LeerinkVoyager Therapeutics price target lowered to $11 from $12 at Leerink

Jay Olson

Oppenheimer

$18

Buy

308.16%

Upside

Reiterated

10/02/25

Voyager Therapeutics (VYGR) Receives a Buy from Oppenheimer

Samantha Semenkow

Citi

$11

Buy

149.43%

Upside

Assigned

09/02/25

Analysts Offer Insights on Healthcare Companies: Cytokinetics (NASDAQ: CYTK), United Therapeutics (NASDAQ: UTHR) and Voyager Therapeutics (NASDAQ: VYGR)

Debjit Chattopadhyay

Guggenheim

$22

Buy

398.87%

Upside

Reiterated

08/07/25

Pipeline updates and extended cash runway bolster our Buy rating with a $22 price target.

Jack Allen

Robert W. Baird

$18

Buy

308.16%

Upside

Reiterated

07/17/25

Voyager Therapeutics (VYGR) Gets a Buy from Robert W. Baird

Pete Stavropoulos

Cantor Fitzgerald

―

Buy

―

Initiated

01/10/25

Cantor Fitzgerald starts Voyager Therapeutics (VYGR) at OverweightCantor Fitzgerald analyst Pete Stavropoulos initiates coverage on Voyager Therapeutics (NASDAQ: VYGR) with a Overweight rating.

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Patrick Trucchio

H.C. Wainwright

$25

Buy

466.89%

Upside

Reiterated

12/03/25

H.C. Wainwright Sticks to Their Buy Rating for Voyager Therapeutics (VYGR)We reiterate our Buy ratings on Alnylam, Biogen, Arrowhead, Denali, Prothena, AC Immune, Voyager, and Alector.

Unknown Analyst

Wells Fargo

Not Ranked

Wells Fargo

$10

Buy

126.76%

Upside

Reiterated

11/12/25

Voyager Therapeutics (VYGR) Receives a Buy from Wells Fargo

Joon Lee

Truist Financial

―

Buy

―

Reiterated

11/11/25

Analysts Offer Insights on Healthcare Companies: Alpha Teknova (NASDAQ: TKNO), Voyager Therapeutics (NASDAQ: VYGR) and Terns Pharmaceuticals (NASDAQ: TERN)

Sumant Kulkarni

Canaccord Genuity

$12

Buy

172.11%

Upside

Reiterated

11/11/25

Voyager Therapeutics (VYGR) Gets a Buy from Canaccord Genuity

Yun Zhong

Wedbush

Buy

81.41%

Upside

Reiterated

11/11/25

Phil Nadeau

TD Cowen

―

Buy

―

Reiterated

11/10/25

Voyager Therapeutics: Strong Financial Position and Promising Pipeline Justify Buy Rating

Lili (Aurélie) Nsongo

Leerink Partners

$12→$11

Buy

149.43%

Upside

Reiterated

11/10/25

Voyager Therapeutics price target lowered to $11 from $12 at LeerinkVoyager Therapeutics price target lowered to $11 from $12 at Leerink

Jay Olson

Oppenheimer

$18

Buy

308.16%

Upside

Reiterated

10/02/25

Voyager Therapeutics (VYGR) Receives a Buy from Oppenheimer

Samantha Semenkow

Citi

$11

Buy

149.43%

Upside

Assigned

09/02/25

Analysts Offer Insights on Healthcare Companies: Cytokinetics (NASDAQ: CYTK), United Therapeutics (NASDAQ: UTHR) and Voyager Therapeutics (NASDAQ: VYGR)

Debjit Chattopadhyay

Guggenheim

$22

Buy

398.87%

Upside

Reiterated

08/07/25

Pipeline updates and extended cash runway bolster our Buy rating with a $22 price target.

Jack Allen

Robert W. Baird

$18

Buy

308.16%

Upside

Reiterated

07/17/25

Voyager Therapeutics (VYGR) Gets a Buy from Robert W. Baird

Pete Stavropoulos

Cantor Fitzgerald

―

Buy

―

Initiated

01/10/25

Cantor Fitzgerald starts Voyager Therapeutics (VYGR) at OverweightCantor Fitzgerald analyst Pete Stavropoulos initiates coverage on Voyager Therapeutics (NASDAQ: VYGR) with a Overweight rating.

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Voyager Therapeutics

1 Month

xxx

Success Rate

9/13 ratings generated profit

Average Return

+5.18%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 69.23% of your transactions generating a profit, with an average return of +5.18% per trade.

3 Months

xxx

Success Rate

8/17 ratings generated profit

Average Return

+3.03%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 47.06% of your transactions generating a profit, with an average return of +3.03% per trade.

1 Year

Jack AllenRobert W. Baird

Success Rate

11/22 ratings generated profit

Average Return

-0.77%

reiterated a buy rating 5 months ago

Copying Jack Allen's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of -0.77% per trade.

2 Years

xxx

Success Rate

8/16 ratings generated profit

Average Return

-7.34%

reiterated a xxx

rating 10 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 50.00% of your transactions generating a profit, with an average return of -7.34% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

VYGR Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, VYGR has received 10 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. VYGR average Analyst price target in the past 3 months is 14.00.

Each month's total comprises the sum of three months' worth of ratings.

VYGR Financial Forecast

VYGR Earnings Forecast

Next quarter’s earnings estimate for VYGR is -$0.51 with a range of -$0.72 to -$0.33. The previous quarter’s EPS was -$0.47. VYGR beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year VYGR has Performed in-line its overall industry.

VYGR Sales Forecast

Next quarter’s sales forecast for VYGR is $10.49M with a range of $3.00M to $24.03M. The previous quarter’s sales results were $13.37M. VYGR beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year VYGR has Performed in-line its overall industry.

VYGR Stock Forecast FAQ

What is VYGR’s average 12-month price target, according to analysts?

Based on analyst ratings, Voyager Therapeutics’s 12-month average price target is 14.00.

What is VYGR’s upside potential, based on the analysts’ average price target?

Voyager Therapeutics has 217.46% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is VYGR a Buy, Sell or Hold?

Voyager Therapeutics has a consensus rating of Strong Buy which is based on 8 buy ratings, 0 hold ratings and 0 sell ratings.

What is Voyager Therapeutics’s price target?

The average price target for Voyager Therapeutics is 14.00. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $25.00 ,the lowest forecast is $8.00. The average price target represents 217.46% Increase from the current price of $4.41.

What do analysts say about Voyager Therapeutics?

Voyager Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.

How can I buy shares of VYGR?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Voyager Therapeutics (VYGR) Stock Forecast & Price Target

VYGR Analyst Ratings

VYGR Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Voyager Therapeutics

VYGR Analyst Recommendation Trends

VYGR Financial Forecast

VYGR Earnings Forecast

VYGR Sales Forecast

VYGR Stock Forecast FAQ

Detailed List of Analyst Forecasts